Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.

Literature DB >> 33177720

Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.

Samik Upadhaya, Svetoslav T Neftelino, Jeffrey P Hodge, Cristina Oliva, Jay R Campbell, Jia Xin Yu.

Abstract

Entities: Gene

Year: 2021 PMID： 33177720 DOI： 10.1038/d41573-020-00204-y

Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694

Keyword Cloud
Cited

× No keyword cloud information.

28 in total

Review 1. Targeting the DNA damage response in immuno-oncology: developments and opportunities.

Authors: Roman M Chabanon; Mathieu Rouanne; Christopher J Lord; Jean-Charles Soria; Philippe Pasero; Sophie Postel-Vinay
Journal: Nat Rev Cancer Date: 2021-08-10 Impact factor: 60.716

Review 2. Generation, secretion and degradation of cancer immunotherapy target PD-L1.

Authors: Dan-Dan Shen; Ya-Ping Bi; Jing-Ru Pang; Li-Juan Zhao; Long-Fei Zhao; Ya Gao; Bo Wang; Hui-Min Liu; Ying Liu; Ning Wang; Yi-Chao Zheng; Hong-Min Liu
Journal: Cell Mol Life Sci Date: 2022-07-11 Impact factor: 9.207

3. Cancer Immunoediting in the Era of Immuno-oncology.

Authors: Matthew M Gubin; Matthew D Vesely
Journal: Clin Cancer Res Date: 2022-09-15 Impact factor: 13.801

4. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.

Authors: Lacey J Padrón; Deena M Maurer; Mark H O'Hara; Eileen M O'Reilly; Robert A Wolff; Zev A Wainberg; Andrew H Ko; George Fisher; Osama Rahma; Jaclyn P Lyman; Christopher R Cabanski; Jia Xin Yu; Shannon M Pfeiffer; Marko Spasic; Jingying Xu; Pier Federico Gherardini; Joyson Karakunnel; Rosemarie Mick; Cécile Alanio; Katelyn T Byrne; Travis J Hollmann; Jonni S Moore; Derek D Jones; Marco Tognetti; Richard O Chen; Xiaodong Yang; Lisa Salvador; E John Wherry; Ute Dugan; Jill O'Donnell-Tormey; Lisa H Butterfield; Vanessa M Hubbard-Lucey; Ramy Ibrahim; Justin Fairchild; Samantha Bucktrout; Theresa M LaVallee; Robert H Vonderheide
Journal: Nat Med Date: 2022-06-03 Impact factor: 87.241

5. Optimal long peptide for flagellin-adjuvanted HPV E7 cancer vaccine to enhance tumor suppression in combination with anti-PD-1.

Authors: Hye Hwa Lee; Seol Hee Hong; Joon Haeng Rhee; Shee Eun Lee
Journal: Transl Cancer Res Date: 2022-06 Impact factor: 0.496

Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.

Review 1. Targeting the DNA damage response in immuno-oncology: developments and opportunities.

Review 2. Generation, secretion and degradation of cancer immunotherapy target PD-L1.

3. Cancer Immunoediting in the Era of Immuno-oncology.

4. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.

5. Optimal long peptide for flagellin-adjuvanted HPV E7 cancer vaccine to enhance tumor suppression in combination with anti-PD-1.

6. Targeting the transcriptional activity of STAT3 by a novel fusion protein.

7. Implications of a granulocyte-high glioblastoma microenvironment in immune suppression and therapy resistance^†.

Review 8. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview.

9. Molecular Mechanisms of PD-1 and PD-L1 Activity on a Pan-Cancer Basis: A Bioinformatic Exploratory Study.

10. STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity.